CEACAM5 and colorectal carcinoma: In one study, DCs mobilized using an FMS-like tyrosine kinase 3 ligand (Flt3L) and pulsed with tailored carcinoembryonic antigen (CEA) peptides improved clinical responses in CRC patients [139].